Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCHER 1017: Dacomitinib in advanced adenocarcinoma of the lung
NCT00818441Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2009
- Primary completion
- Apr 2012
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 5
01
Overview
A Phase 2 trial of dacomitinib in lung adenocarcinoma, sponsored by Pfizer. Started Mar 2009; status: completed.
02
Drugs
dacomitinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT00818441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00818441.